With Ideaya deal, GSK bulks up synthetic lethality side of oncology business

GSK and Ideaya’s deal is the second in a month to move a pharma deeper into synthetic lethality

A deal with Ideaya gives GSK a path to growing its synthetic lethality pipeline, a corner of the pharma’s cancer rebuild still primarily centered around PARP inhibitor Zejula.

On Tuesday, GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) and Ideaya Biosciences Inc. (NASDAQ:IDYA) announced a partnership covering three preclinical programs targeting the biosynthetic enzyme MAT2A, the DNA polymerase POLQ, and the DNA helicase WRN.

Ideaya has solved the crystal structures

Read the full 647 word article

How to gain access

Continue reading with a
two-week free trial.